Kazazian Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Kazazian Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$124K	Hold	858	–	–	0.17%	50
2019 Q2	$77K	Sell	858 -111	-11%	-$8.91K	0.09%	62
2019 Q1	$85K	Sell	969 -800	-45%	-$88.7K	0.12%	58
2018 Q4	$249K	Buy	1,769 +600	+51%	+$101K	0.34%	48
2018 Q3	$299K	Sell	1,169 -209	-15%	-$57.8K	0.28%	68
2018 Q2	$351K	Buy	+1,378	New	+$341K	0.32%	59

Other funds holding KPTI

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Kazazian Asset Management's KPTI Position: Q3 2019 in Review

Kazazian Asset Management held its Karyopharm Therapeutics (KPTI) position steady in Q3 2019 at 858 shares worth $124K. The position accounts for 0.17% of the portfolio, ranked #50.

Kazazian Asset Management first reported a position in KPTI in Q2 2018 and has held it in 6 quarters since. The position peaked at $351K in Q2 2018. 106 funds tracked by Wall St. Rank hold KPTI as of Q3 2019.

Kazazian Asset Management held 858 shares of Karyopharm Therapeutics worth $124K as of Q3 2019.
Kazazian Asset Management left its Karyopharm Therapeutics share count unchanged in Q3 2019.
Karyopharm Therapeutics made up 0.17% of Kazazian Asset Management's portfolio in Q3 2019, its #50 holding.
Kazazian Asset Management first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 6 quarters since.
Kazazian Asset Management's Karyopharm Therapeutics position peaked at $351K in Q2 2018.
106 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.